TGFB1 and hypertensive disorder: The latest randomized controlled double-blind clinical trial also demonstrated that Carvedilol significantly reduced cardiac troponin levels and diastolic dysfunction [33] and reduced biomarkers of tissue fibrosis and inflammation in hypertensive disease models, such as TGFβ [34].